In This Section

Program

Please note that this meeting will take place as an in-person event in Philadelphia and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the registration page for details.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Monday, March 23

TUESDAY, MARCH 24

WEDNESDAY, MARCH 25

Monday, March 23

REGISTRATION

3-8 p.m.

WELCOME AND OPENING Keynotes

5-6:15 p.m.

  • 5:05 p.m. | Introduction of Keynote Speaker 1
    Stephen J. Bagley, University of Pennsylvania, Philadelphia, Pennsylvania
  • 5:10 p.m. | How to target malignant neural networks in brain cancer
    Frank Winkler Heidelberg University, Heidelberg, Germany 
  • 5:40 p.m. | Introduction of Keynote Speaker 2
    Mario Suva, Massachusetts General Hospital, Boston, Massachussetts
  • 5:45 p.m. | The role of injury programs in gliomagenesis
    Simona Parrinello, University College London (UCL) Cancer Institute, London, United Kingdom
     

Break

6:15-6:30 p.m.

Panel Discussion

6:30-7:30 p.m.

  • Mario L. Suvà, Harvard Medical School, Broad Institute of MIT and Harvard, Boston, Massachusetts
  • Michelle Monje, Stanford Hospital, Stanford, California
  • Stephen Bagley, University of Pennsylvania, Philadelphia, Pennsylvania

Additional panelists to be announced

Opening Reception 

7:30-9:30 p.m.

Tuesday, March 24

CONTINENTAL BREAKFAST

7-8 a.m.

Roundtable Talks

7:15 -8:15 a.m.

Plenary Session 1: The Neuroscience of Gliomas  

8:30 a.m.

Session Chair: Michelle Monje, Stanford Hospital, Stanford, California

  • 8:35 a.m. | Michelle Monje 
  • 8:55 a.m. | Benjamin Deneen, Baylor College of Medicine, Houston, Texas
  • 9:15 a.m. | Shawn Hervey-Jumper, University of California San Francisco, San Francisco, California

Break 

10-10:15 a.m. 

Plenary Session 2: Advances in NeuroImmunoOncology 

10:15-11:40 a.m.

  • 10:20 a.m. | Redefining and targeting immunosuppressive myeloid cells in brain tumors
    Tyler E. Miller, Case Western Reserve University School of Medicine, Cleveland, Ohio
  • 10:40 a.m. | Exhausted CD8 T cell regulation of low-grade glioma growth
    David Gutmann, Washington University School of Medicine in St. Louis, St. Louis Missouri
  • 11 a.m. | Glioma Immunotherapy 
    Lukas Bunse, DKFZ German Cancer Research Center, Heidelberg, Germany

Additional speakers to be announced

Lunch on own

11:40 a.m.-1 p.m.

Plenary Session 3: Cellular Therapies for Nervous System Tumors 

1-2:30 p.m.

Session Chair: Stephen J. Bagley, University of Pennsylvania, Philadelphia, Pennsylvania

  • 1:05 p.m. | Donald M. O’Rourke, University of Pennsylvania, Philadelphia, Pennsylvania
  • 1:25 p.m. | Christine Brown, City of Hope National Medical Center, Durante, California
  • 1:45 p.m. | Cell state-directed CAR-T cell therapies for glioma
    Christopher Mount, Massachusetts General Hospital, Boston, Massachusetts

Break

2:30-2:45 p.m.

Plenary Session 4: Brain Borders and CNS Trafficking

2:45–4:15 p.m.

  • 2:50 p.m. | Ungating barriers to the trafficking of tumor biomarkers and therapeutics in infiltrating CNS tumors
    Graeme F. Woodworth, University of Maryland, Baltimore, Maryland
  • 3:10 p.m. | Jonathan Kipnis, Washington University School of Medicine in St. Louis, St. Louis, Missouri
  • 3:30 p.m. | Lipid nanoparticles for overcoming biological barriers to mRNA delivery to the brain
    Michael John Mitchel, University of Pennsylvania, Philadelphia, Pennsylvania

Break

2:30-2:45 p.m.

Proffered Talks

4:30-6 p.m.

Poster Session & Reception 

6-8 p.m.

Wednesday, March 25

CONTINENTAL BREAKFAST

7-8 a.m.

Plenary Session 5: Next Generation Diagnostics and Biomarkers 

8-9 a.m.

  • 8:05 a.m. | Craig Horbinski, The Mayo Clinic, Jackson, Florida
  • 8:25 a.m. | Tumor Derived DNA as a Diagnostic Tool in Neuro-Oncology
    Chetan Bettegowda, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • 8:45 a.m. | Advantages and challenges of amino acid PET imaging in patients with brain tumors
    Norbert Galldiks, University of Cologne, Cologne, Germany 

Additional speaker to be announced

Break 

9:30-9:45 a.m. 

Plenary Session 6: Updates in Brain Metastases and Leptomeningeal Disease 

9:45-11:15 a.m.

  • 9:50 a.m. | Adrienne Boire, Memorial Sloan Kettering Cancer Center, New York, New York
  • 10:10 a.m. | Humsa Venkatesh, Harvard Medical School/Brigham and Women’s Hospital, Boston, Massachusetts
  • 10:30 a.m. | Josh Neman-Ebrahim, Keck School of Medicine, Los Angeles, California

Break

11:15-11:30 a.m.

Plenary Session 7: Solving Tumor Heterogeneity: Spatial and 3D Genomics 

11:30 a.m.-1 p.m.

Session Chair: Mario Suva, Massachusetts General Hospital, Boston, Massachusetts

  • 11:35 a.m. | Mario Suva
  • 11:55 a.m. | Joseph F. Costello, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
  • 12:15 p.m. | Antonio Iavarone, University of Miami, Miami, Florida

Closing Remarks & Departure

1-1:15 p.m.